A. Mills

发表

Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1.

T. Wrin, J. Mellors, R. Begley, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males.

J. Block, A. Mills, S. Schrader, 2005, Clinical cornerstone.

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV

P. Sax, K. Mounzer, J. Eron, 2020, PloS one.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

D. Dieterich, S. Henn, M. Ramgopal, 2015, The New England journal of medicine.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

R. Haubrich, P. Cahn, T. Wilkin, 2007, The Lancet.

Uninsured free clinic patients’ experiences and perceptions of healthcare services, community resources, and the Patient Protection and Affordable Care Act

Justine J. Reel, A. Kamimura, Jeanie Ashby, 2016 .

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

M. Murray, M. Ramgopal, J. Mrus, 2019, HIV research & clinical practice.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

J. van Lunzen, M. Cavassini, C. Orkin, 2016, The Lancet. Infectious diseases.

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

S. Swindells, Kimberly Smith, E. Overton, 2021, The Patient - Patient-Centered Outcomes Research.

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

W. Spreen, D. Margolis, A. Mills, 2021, AIDS (London, England).

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study

J. Mrus, A. Oglesby, L. Brunet, 2019, Infectious Diseases and Therapy.

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice

Felix Carpio, E. Dejesus, R. Hsu, 2016, Clinical Drug Investigation.

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b

K. White, M. Markowitz, H. Stellbrink, 2014, The Lancet. Infectious diseases.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials†

H. Stellbrink, M. Das, E. Daar, 2018, HIV medicine.

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.

M. Ramgopal, E. Dejesus, S. Segal-Maurer, 2018, AIDS research and human retroviruses.

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

S. Swindells, S. Letendre, H. Crauwels, 2019, The Journal of antimicrobial chemotherapy.

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects

K. Tashima, S. Letendre, S. Piscitelli, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

The DUET trials: etravirine in the management of treatment-experienced HIV-1-infected patients

A. Mills, 2010 .

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

J. Gallant, M. Das, S. Oka, 2016, Journal of Acquired Immune Deficiency Syndromes.

Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens

K. White, C. Cohen, A. Cheng, 2013, HIV clinical trials.

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials

P. Cahn, N. Clumeck, J. Molina, 2010, International journal of STD & AIDS.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

K. Ruxrungtham, M. Nelson, L. Lavreys, 2009, AIDS.

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

K. White, P. Sax, A. Zolopa, 2013, Journal of acquired immune deficiency syndromes.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.

W. Spreen, D. Margolis, A. Mills, 2021, AIDS (London).

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

M. Bloch, S. Hodder, Bill Guyer, 2013, HIV clinical trials.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

A. Lazzarin, M. Saag, P. Cahn, 2011, The Lancet.

Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data

D. Ward, R. Ebrahimi, A. Cheng, 2014, HIV clinical trials.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

K. White, P. Sax, A. Zolopa, 2012, The Lancet.

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

E. Negredo, J. Gallant, A. Antinori, 2018, AIDS.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients

A. Zolopa, J. Gallant, C. Cohen, 2012 .

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

K. White, C. Orkin, C. Cohen, 2014, AIDS patient care and STDs.

A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

K. White, P. Sax, A. Zolopa, 2014, Journal of acquired immune deficiency syndromes.

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

W. Spreen, D. Margolis, A. Mills, 2020 .

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

D. Podzamczer, K. White, J. Gallant, 2017, The Lancet.

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

K. White, D. Ward, P. Sax, 2017, The lancet. HIV.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of Acquired Immune Deficiency Syndromes.

Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and T

R. Speck, A. Pozniak, J. Berenguer, 2015, The Patient - Patient-Centered Outcomes Research.

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

D. Ward, P. Sax, A. Cheng, 2018, AIDS.

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Yong Gao, E. Arts, Shilei Ding, 2016, Retrovirology.

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

R. Haubrich, B. Clotet, C. Katlama, 2010, Antiviral therapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of the safety, pharmacokinetics, and potential therapeutic value

J. Norrie, A. Akram, K. Dhaliwal, 2021, medRxiv.

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies

C. Hung, J. Slim, J. Eron, 2019, Journal of Infection and Public Health.

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

S. Walmsley, M. Murray, Jenny Huang, 2020, AIDS and Behavior.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Selected CNS Outcomes Among INSTI Antiretrovirals

D. Wohl, R. Mera, A. Mills, 2017, Open Forum Infectious Diseases.

Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study

D. Podzamczer, H. Valdez, M. Leal, 2013, Journal of acquired immune deficiency syndromes.

HIV-1 DNA Resistance Testing Informs the Successful Switch to a Single Tablet Regimen

C. Petropoulos, A. Stoker, Charles, 2019 .

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, H. Stellbrink, F. Post, 2017, The lancet. HIV.

Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents

J. Priest, K. Schulman, A. Oglesby, 2021, Open forum infectious diseases.

The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review

J. Aberg, S. Moreno, A. Clark, 2023, Antiviral therapy.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment‐naïve patients

S. Storfer, E. Dejesus, L. Bhatti, 2011, International journal of clinical practice.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis

D. Ward, C. Cohen, C. Hicks, 2007, AIDS.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, D. Podzamczer, A. Lazzarin, 2017, The lancet. HIV.

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

T. Wrin, J. Mellors, R. Begley, 2021, Science Translational Medicine.

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.

C. Hung, J. Slim, J. Eron, 2020, Journal of acquired immune deficiency syndromes.

Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks

B. Clotet, A. Antinori, C. Hicks, 2011 .

Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study

W. Spreen, J. Baril, E. Dejesus, 2022, Open forum infectious diseases.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

A. Lazzarin, M. Saag, P. Cahn, 2011, The Lancet.

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Eric J. Arts, Stefan Schneider, Yong Gao, 2016, Retrovirology.

Untreated HCV in HIV/HCV co-infection: Data from the TRIO network

P. Sax, J. Eron, D. Wyles, 2018 .

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

M. Ramgopal, A. Mills, O. Osiyemi, 2024, The lancet. HIV.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.